CLSD

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.58, close to its 52-week low of $1.26. According to TipRanks.com, Wolleben is ranked 0 out of 5 stars with an average return of -9.9% and a 32.7% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $9.67.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-clearside-biomedical-clsd?utm_source=advfn.com&utm_medium=referral